Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine
Aurora, Colorado, 80045, United States
NCT Number: NCT02114333
This study will compare the two vaccines that have been developed to prevent and/or lessen the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other, herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an ingredient that may enhance the body's immune response to the vaccine, and is currently investigational. The vaccines are being compared to assess their ability to stimulated protection against shingles. The study will provide an opportunity to determine the safety profile of each vaccine in a single trial. The study will also look at the effect of age on the immune response to the two vaccines and on the persistence of these responses.
Looking for future studies?
Notify Me50 year–85 year
All sexes
Interventional
Phase 1
Aurora, Colorado, 80045, United States
160 people from the Denver area will participate. Duration is up to 5 years with 10-12 visits in that period. Subjects are randomized into one of 4 arms to receive either Zostavax or HZ/su. In this single blind study all subjects receive 2 injections: one at the first visit (Day 0) and the second at Day 60. HZ/su subjects will receive vaccine at both visits; Zostavax subjects will receive vaccine at the first visit and a placebo at the Day 60 visit. Blood is collected from all subjects at most visits. Some subjects spit into a tube for saliva collection. A urine sample is collected prior to vaccination if subject is a woman of childbearing potential. Subjects are asked to complete a diary to record any reactions in the 30 days after each injection. The Day 90 visit is the last one until the annual visits for blood draws begin at Day 365. Some subjects are also seen at Year 2 and Year 4; all subjects are seen at Year 5 for blood draw.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
0.65ml, subcutaneous
0.5ml, intramuscular
Other names: Recombinant vaccine
0.65ml, subcutaneous
Other names: normal saline
Time frame: Measured up to Day 730
Time frame: Measured up to Day 730
Time frame: Within 30 days of each vaccination
University of Colorado, Denver
Other
A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04099706
Chronic Pain, DNA Virus Infections
Odense, Funen, Denmark
View Trial DetailsNCT05245838
DNA Virus Infections, Herpes Zoster
Blacktown, New South Wales, Australia
View Trial DetailsNCT01600079
Chickenpox, DNA Virus Infections
View Trial DetailsNCT01527370
DNA Virus Infections, Herpes Zoster
View Trial Details